Drug Approval Process in Europe

The drug approval process in the European Union (EU) is a comprehensive regulatory framework designed to ensure the safety, efficacy, and quality of medicinal products. With the aim of harmonizing standards across member states, the EU has established various procedures for the marketing authorization of drugs. This article provides an overview of these procedures and their significance in the European drug approval process.

Mutual Recognition Procedure

• The Mutual Recognition Procedure (MRP) was introduced in 1938 to facilitate the marketing authorization of pharmaceutical products in EU countries. Its primary objective was to establish a unified standard for product review among national regulatory authorities. 
• Under the MRP, a product undergoes assessment by both the national regulatory authority and the Committee for Proprietary Medicinal Products (CPMP) for high-technology or biologically derived products. This procedure provided a streamlined approach to product review, allowing the mutual recognition of marketing authorizations granted by one member state in others.

Centralized Procedure

• The Centralized Procedure is a mandatory regulatory pathway for certain categories of medicines in the EU. It was established in 1993 to ensure a centralized review and approval process for medicines derived from biotechnology processes, as well as those intended for the treatment of specific diseases such as cancer, HIV/AIDS, diabetes, neurodegenerative disorders, autoimmune diseases, and rare diseases (designated as "Orphan medicines"). 
• The Committee for Human Medicinal Products (CHMP) evaluates the applications received by the European Medicines Agency (EMA) during the centralized procedure. The CHMP may delegate assessment work to a member state, known as the "rapporteur," based on the applicant's preference. 
• After a thorough evaluation, the CHMP provided its opinion to the European Commission within 210 days. If a positive opinion is received, the European Commission requests comments from other member states. Upon successful completion of this process, a marketing authorization is issued, valid throughout the EU for a period of five years, with the possibility of extension.

Decentralized Procedure

• The Decentralized Procedure is employed when an applicant seeks marketing authorizations in multiple EU member states, and the centralized procedure is not mandatory. Under this procedure, the applicant submits an application to the competent authorities of each member state in which they intend to obtain authorization. 
• The application includes comprehensive information on the quality, efficacy, safety, and administrative details of the medicinal product. One member state is designated as the Reference Member State (RMS), while others become Concerned Member States (CMSs). 
• The RMS prepares a draft assessment report, and within 14 days, the CMSs and the RMS validate the application. The RMS then drafts the summary of product characteristics, labeling, and package leaflet within 120 days. The assessment report can be approved within 90 days. In cases where potential serious risks to public health arise, the CMSs promptly inform other member states, the RMS, and the applicant, and a decision is made within 30 days.

ALSO READ: Regulatory Requirements for the Drug Approval Process in the USA

• If an agreement cannot be reached among member states, the CHMP intervenes and makes the final decision, considering the applicant's explanations. This procedure provides a mechanism for obtaining marketing authorizations in multiple member states through a collaborative approach.

Nationalized Procedure

The Nationalized Procedure allows applicants to obtain marketing authorization in a single member state only. In this procedure, the applicant submits an application to the competent authority of the respective member state. The Nationalized Procedure is typically used for new active substances that do not fall under the mandatory requirements of the centralized procedure. It provides a more localized approach to obtaining marketing authorization for pharmaceutical products.

Mutual Recognition Procedure

• The Mutual Recognition Procedure (MRP) enables applicants to obtain marketing authorization in member states other than the Reference Member State (RMS), where the drug has already been approved. Under the MRP, the applicant submits an identical dossier to all EU member states where authorization is sought. 
• Once an evaluating Member State (RMS) decides to assess the product, it notifies other Member States (CMSs) to whom applications have also been submitted. The RMS issues a report on its findings, and this report serves as the basis for further decision-making by the CMSs. 
• The Mutual Recognition Procedure is commonly utilized by the generic industry to gain marketing authorizations in multiple member states simultaneously. This process typically takes approximately 390 days.

Conclusion

The drug approval process in Europe encompasses several regulatory procedures that ensure the safety, efficacy, and quality of medicinal products. The Mutual Recognition Procedure, Centralized Procedure, Decentralized Procedure, and Nationalized Procedure provide different pathways for obtaining marketing authorization across EU member states. 

These procedures have been designed to streamline the review and approval of pharmaceutical products, facilitating the availability of safe and effective medications for patients throughout Europe. By harmonizing standards and promoting collaboration among regulatory authorities, the EU ensures a robust and efficient drug approval process that protects public health and fosters innovation in the pharmaceutical industry.

ALSO READ: Drug Regulatory Affairs